New Era for Ripple's XRP: PFMCrypto Launches Zero-Hardware XRP Cloud Mining with Daily Payouts
New York, NY, July 20, 2025 (GLOBE NEWSWIRE) — As Ripple's XRP ecosystem continues to gain global traction, PFMCrypto is proud to introduce a major advancement in accessible crypto mining: the launch of XRP-focused cloud mining contracts. Now available on both web and mobile platforms, these flexible short-term contracts allow users to mine XRP remotely and receive daily XRP rewards—with no mining hardware, no complicated setup, and no prior experience required. For the first time, everyday users can actively participate in the XRP economy through a streamlined, all-in-one platform.
Visit https://pfmcrypto.net or download the PFMCrypto app today.
XRP Cloud Mining Is Here—Simple, Smart, and Rewarding.Long recognized for its role in cross-border payments and institutional finance, XRP now enters a new phase through PFMCrypto's latest innovation: user-friendly cloud mining.Users can mine XRP directly, or take advantage of PFMCrypto's intelligent AI engine, which automatically shifts mining power toward the most profitable assets—including BTC, ETH, DOGE, USDC, and more. Earnings are paid out daily in the cryptocurrency of your choice, providing a reliable income stream regardless of market volatility.
Whether you're a beginner or a seasoned investor, PFMCrypto's platform empowers you to earn consistent crypto rewards—anytime, from anywhere.
Key Features of PFMCrypto's XRP Cloud Mining Contracts:
– Full XRP Integration: Deposit, purchase, mine, and withdraw XRP within one secure platform.
– Multi-Coin Mining Support: Earn rewards in BTC, ETH, DOGE, USDC, USDT, SOL, LTC, or BCH.
– AI Revenue Optimization: Proprietary algorithms allocate mining power for maximum profitability.
– 100% Remote Access: No equipment required—accessible via mobile app or browser.
– Capital Protection: Every contract includes full principal return at maturity to reduce risk.
Mining Contracts for Every Budget and Strategy:PFMCrypto offers a variety of flexible mining contracts that support XRP-based deposits and withdrawals. Each contract is designed for predictable income and effective risk control:$10 Contract – 1 Day – Earn $0.66 (Free with signup bonus)$100 Contract – 2 Days – Earn $3.00 daily + $2 bonus$500 Contract – 5 Days – Earn $6.15 daily$5,000 Contract – 30 Days – Earn $78.50 daily$20,000 Contract – 45 Days – Earn $380.00 dailyWhether you're exploring crypto mining or building a long-term passive income portfolio, PFMCrypto provides secure, low-risk contracts with transparent daily earnings in XRP.
Explore more contracts at: https://pfmcrypto.net
Why PFMCrypto's XRP Mining Stands Out?
– Accessible to All: No technical skills, no hardware, no complications—just tap and earn.
– XRP-Native Functionality: Handle XRP from deposit to withdrawal within one ecosystem.
– Smart, Stable Returns: AI-powered mining strategy delivers steady earnings across assets.
– Built-in Flexibility: Choose to mine XRP or diversify into other top cryptos—all in one contract.
– Global, Instant Access: Start mining securely via browser or app from anywhere in the world.
Start Earning in 3 Simple Steps:
1. Sign Up – Create your account and receive a $10 welcome bonus.
2. Choose a Plan – Select from short- or long-term contracts (1–60 days available).
3. Start Earning – Track daily rewards and withdraw in your preferred token.
XRP Mining for a Digital Future:Since 2018, PFMCrypto has helped millions of users generate passive crypto income through secure, intelligent, cloud-based mining. With the launch of XRP mining, the platform combines institutional-grade infrastructure with unmatched retail accessibility.Now, users can mine XRP directly or diversify their earnings across major digital assets—all through a fully remote, user-friendly environment.
'XRP has always been fast, efficient, and scalable,' said a PFMCrypto spokesperson. 'Now, it's also mineable—securely, remotely, and profitably. We've eliminated the barriers so anyone can participate in XRP's future growth.'
While markets shift, daily mining income remains consistent—and now, more accessible than ever.
Join the XRP mining revolution today at: https://pfmcrypto.net
Download the PFMCrypto app on iOS or Android.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
an hour ago
- Hamilton Spectator
Helius Announces Positive Outcome of the Portable Neuromodulation Stimulator PoNS® Stroke Registrational Program and Upcoming Submission to FDA Under Breakthrough Designation
NEWTOWN, Pa., July 21, 2025 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced positive outcome from the PoNS (Portable Neuromodulation Stimulator) Stroke Registrational Program (SRP) supporting a planned FDA submission seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under the current Breakthrough Device Designation. The key primary outcomes from the SRP indicate that: 'The successful execution of the PoNS SRP and the positive results of the clinical trials mark an important milestone in advancing the standard of care for stroke and offer individuals suffering from gait/balance disability a meaningful therapeutic option to rehabilitate and regain their functionality,' stated Antonella Favit-Van Pelt, M.D., Ph.D., Helius' Chief Medical Officer. 'We look forward to releasing the SRP's study results this quarter and to continuing working closely with FDA under the upcoming application for authorization of the Agency's breakthrough designated PoNS device.' Helius started the SRP in March 2024 after a positive interaction with the FDA on the data development program, study design, and endpoints. The SRP includes two pivotal Sponsor-initiated clinical studies: a double-blind, randomized controlled trial and a single-arm trial, which began in April 2024. The SRP is also supported by a pilot investigator-initiated, double-blind randomized controlled trial by Dr. Steve Kautz and Dr. Mark Bowden of MUSC (SC) and Brook Rehabilitation (FL) respectively, which began late in the fall of 2023. All three clinical trials enrolled patients from the same patient population and shared the same study structure/endpoints aimed at establishing the efficacy and safety of PoNS in people with gait deficit due to chronic stroke. A total of 159 patients were enrolled across the three studies, with 130 patients completing both the 12-week study treatment phase and the 12-week post treatment follow-up period, at 10 clinical sites including centers of excellence for stroke rehabilitation across the US and Canada. Study participants received the (active or sham) study treatment in combination with physical therapy according to the current guidelines for functional rehabilitation of people with chronic stroke. The primary endpoints for all three studies included improvement of gait and/or balance deficit after 12 weeks of study treatment with two key multiplicity-controlled secondary endpoints assessing risk of falling and 12-week durability of effect. The double-blind randomized clinical trial met the primary endpoint of demonstrating statistically significant greater improvements in gait and/or balance deficit due to stroke with active PoNS Therapy with and without including additional data from an open label study using statistical methods to balance baseline characteristics. The studies also demonstrated minimal incidence of adverse events and confirmed good treatment tolerability. 'More than 7 million patients suffer from the symptoms of stroke and about 80% of them have balance and gait deficit, resulting in a large addressable market with a high risk of falling,' said Dane Andreeff, Helius' CEO. 'We look forward to a positive outcome of the submission to the FDA and to bringing this impactful treatment to everyone living with the consequences of a stroke.' The PoNS has not yet been approved in the United States for use in stroke rehabilitation and remains investigational for this use. Helius is planning to file a submission to the FDA for an indication in stroke during the third quarter of 2025 under its current FDA breakthrough designation for stroke. About the PoNS Device and PoNS Therapy The Portable Neuromodulation Stimulator ('PoNS') is an innovative, non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece connected to a controller and it's used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from MS and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. PoNS has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in Canada, where it received authorization for sale in three indications: (i) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke and is to be used in conjunction with physical therapy; (ii) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury ('mmTBI') and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit . About Helius Medical Technologies, Inc. Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain's ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company's first commercial product is the Portable Neuromodulation Stimulator. For more information about the PoNS or Helius Medical Technologies, visit . Cautionary Disclaimer Statement Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as 'believe,' 'expect,' 'continue,' 'will,' 'goal,' 'aim' and similar expressions. Such forward-looking statements include, among others, statements regarding future presentation and uses of the PoNSTEP study results, the availability of commercial reimbursement and the uses and effectiveness of PoNS and PoNS Therapy. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company's expectations include uncertainties associated with the Company's capital requirements to achieve its business objectives, availability of funds, the Company's ability to find additional sources of funding, manufacturing, labor shortage and supply chain risks, including risks related to manufacturing delays, the Company's ability to obtain national Medicare insurance coverage and to obtain a reimbursement code, the Company's ability to continue to build internal commercial infrastructure, secure state distribution licenses, market awareness of the PoNS device, future clinical trials and the clinical development process, the product development process and the FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the 'Risk Factors' section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at or . The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law. Investor Relations Contact Philip Trip Taylor Gilmartin Group investorrelations@
Hamilton Spectator
an hour ago
- Hamilton Spectator
BTCS Inc. ETH and Cash Market Value Now $242 Million
Agrees to issue approximately $10 Million Convertible Notes at $13 per share, a 198% premium to July 18 close $189 million raised year-to-date through hallmark DeFi/TradFi Accretion Flywheel strategy SILVER SPRING, MD, July 21, 2025 (GLOBE NEWSWIRE) — BTCS Inc. (Nasdaq: BTCS ) ('BTCS' or the 'Company'), a blockchain technology-focused company, short for Blockchain Technology Consensus Solutions, today announced that the combined market value of its 55,788 ETH holdings, cash1, and other liquid holdings are approximately $242.2 million, based on an ETH price of $3,600. Additionally, the Company has agreed to issue $10 million in convertible notes through its previously established $56 million arrangement with ATW Partners LLC. While the funding is extremely modest relative to the $189 million raised year-to-date, the nearly 200% conversion premium is consistent with, and further demonstrates, BTCS's execution of its hallmark DeFi/TradFi Accretion Flywheel strategy. The Company limited this financing to $10 million as part of its strategy to maintain financial flexibility for opportunistic future leverage while maintaining its loan-to-value ratio below 40%. This approach aligns with BTCS's commitment to maximizing ETH exposure and minimizing shareholder dilution. DeFi/TradFi Accretion Flywheel Update BTCS is successfully executing its DeFi/TradFi Accretion Flywheel capital formation strategy, leveraging both decentralized and traditional finance to expand its ETH holdings, capitalize on its vertically integrated operations, and enhance shareholder value. The Company has raised capital through a mix of at-the-market equity sales, above-market convertible debt, and DeFi-based borrowing, executed in alignment with its strategy to optimize ETH exposure while actively managing dilution, as detailed below. Year-to-Date Funding Summary ATM Sales: $132 million1 (70%) Above-Market Convertible Debt: $17 million (9%) Aave Stablecoin Loans (DeFi): $40 million (21%) Total year-to-date funding: $189 million Total Crypto & Cash Assets: $242 million1 ETH Holdings: 55,788 (average cost per ETH: $2,846), a 516% year-to-date increase ' We believe that BTCS is the most financially and operationally leveraged Ethereum play in public markets today, ' said Charles Allen, CEO of BTCS. ' Our vertically integrated block-building and node operations are generating record revenue, and when combined with solid execution of our hallmark DeFi/TradFi Accretion Flywheel, BTCS offers investors scalable, high-growth exposure to Ethereum. ' ________________________________ 1 Inclusive of $28.4 million ATM sales at $7.9 per share pending settlement and funds from the pending closing of the $10 million convertible note. Above Market Convertible Note Financing The $10 million principal amount notes are convertible into common stock at a fixed conversion price of $13 per share, representing a 198% premium over the Company's $6.57 closing stock price on Friday, July 18, 2025. The notes have a two-year maturity, expiring on July 21, 2027, include a 5% original issue discount, and bear interest at an annual rate of 6%. In connection with the note issuance, five-year warrants will be issued at closing to purchase 879,375 shares of common stock at an exercise price of $8 per share, representing a 122% premium to the closing price on Friday, July 18, 2025. The funding is expected to close on or before Tuesday, July 22, 2025. Notably, the financing involves no investment banking fees or restrictive terms typically associated with using an investment bank or placement agent, which could hinder the execution of the Company's DeFi/TradFi Accretion Flywheel strategy. As part of the financing terms, the Company agreed that, while the notes remain outstanding, it will not amend its non-convertible Series V Preferred Shares to allow for conversion into common stock for a period of 18 months. Capital Structure Update To help investors accurately assess BTCS's intrinsic value and compare it with its peers, we're providing an updated breakdown of our capital structure. This summary provides additional information to supplement our SEC filings. Approximately 16 million shares of Series V are now excluded from the fully diluted share count, as they are non-convertible and, under the terms of the note financing, cannot be amended to be convertible for 18 months. In light of the restriction and given the new administration's growing acceptance of crypto and the broader recognition that real-world assets will be tokenized, the Company may re-explore various options to create liquidity for the Series V preferred shares, including potential tokenization on Ethereum's blockchain. However, it is still very early, and the Company can provide no guarantees or assurances that it will be able to tokenize or create liquidity for the Series V and may ultimately seek to convert the Series V to common stock when the restriction expires. As such, the Series V has been excluded from the table above. About BTCS: BTCS Inc. ('BTCS' or the 'Company'), short for Blockchain Technology Consensus Solutions, is a U.S.-based Ethereum-first blockchain technology company committed to driving scalable revenue and ETH accumulation through its hallmark strategy, the DeFi/TradFi Accretion Flywheel, an integrated approach to capital formation and blockchain infrastructure. By combining decentralized finance ('DeFi') and traditional finance ('TradFi') mechanisms with its blockchain infrastructure operations, comprising NodeOps (staking) and Builder+ (block building), BTCS offers one of the most sophisticated opportunities for leveraged ETH exposure, driven by scalable revenue generation and a yield-focused ETH accumulation strategy. Discover how BTCS offers operational and financial leveraged exposure to Ethereum through the public markets at . Cautionary Note Regarding Forward-Looking Statements Certain statements in this press release constitute 'forward-looking statements' within Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 including statements regarding creating high growth exposure to Ethereum, creating liquidity for Series V, and closing of the $10 million note offering. Words such as 'may,' 'might,' 'will,' 'should,' 'believe,' 'expect,' 'anticipate,' 'estimate,' 'continue,' 'predict,' 'forecast,' 'project,' 'plan,' 'intend' or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon assumptions and are subject to various risks and uncertainties, including without limitation market conditions, regulatory issues and requirements, unanticipated issues with our At-The-Market Offering facility, unexpected issues with Builder+, as well as risks set forth in the Company's filings with the Securities and Exchange Commission including its Form 10-K for the year ended December 31, 2024 which was filed on March 20, 2025. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements, whether as a result of new information, future events or otherwise, except as required by law. For more information follow us on: Twitter: LinkedIn: Facebook: Investor Relations: Charles Allen – CEO X (formerly Twitter): @Charles_BTCS Email: ir@ A photo accompanying this announcement is available at
Hamilton Spectator
an hour ago
- Hamilton Spectator
Rogers Announces Results and Upsize of its Cash Tender Offers for Eight Series of U.S. Dollar Debt Securities
TORONTO, July 21, 2025 (GLOBE NEWSWIRE) — Rogers Communications Inc. ('Rogers' or the 'Company') (TSX: RCI.A and RCI.B; NYSE: RCI) announced (i) the release of the results of its previously announced eight separate offers (the 'Offers') to purchase for cash any and all of the outstanding notes of each series listed in the table below (collectively, the 'Notes'), and (ii) that Rogers is increasing the aggregate Total Consideration payable for all Notes it will accept for purchase in the Offers, excluding accrued but unpaid interest, from the previously announced amount of US$1,250,000,000 to US$1,400,000,000 (the 'Consideration Cap Amount'). The increased Consideration Cap Amount is sufficient to enable Rogers to accept for purchase all (1) 4.350% Senior Notes due 2049, (2) 3.700% Senior Notes due 2049, (3) 4.300% Senior Notes due 2048, (4) 4.500% Senior Notes due 2043 and (5) 5.000% Senior Notes due 2044, in each case, that were validly tendered prior to or at the Expiration Date and not validly withdrawn (as well as all of the Notes of such series that were tendered pursuant to the Guaranteed Delivery Procedures). The Offers were made upon the terms and subject to the conditions set forth in the Offer to Purchase dated July 11, 2025 relating to the Notes (the 'Offer to Purchase') and the notice of guaranteed delivery attached as Appendix A thereto (the 'Notice of Guaranteed Delivery' and, together with the Offer to Purchase, the 'Tender Offer Documents'). Capitalized terms used but not defined in this news release have the meanings given to them in the Offer to Purchase. The Offers expired at 5:00 p.m. (Eastern time) on July 18, 2025 (the 'Expiration Date'). The Guaranteed Delivery Date is 5:00 p.m. (Eastern time) on July 22, 2025. The Settlement Date will be July 23, 2025. According to information provided by D.F. King & Co., Inc., the Information and Tender Agent in connection with the Offers, US$2,765,201,000 combined aggregate principal amount of Notes were validly tendered prior to or at the Expiration Date and not validly withdrawn. In addition, US$24,666,000 combined aggregate principal amount of Notes were tendered pursuant to the Guaranteed Delivery Procedures and remain subject to the Holders' performance of the delivery requirements under such procedures. The table below provides certain information about the Offers, including the aggregate principal amount of each series of Notes validly tendered and not validly withdrawn at or prior to the Expiration Date and the aggregate principal amount of Notes reflected in Notices of Guaranteed Delivery delivered at or prior to the Expiration Date pursuant to the Tender Offer Documents. Overall, US$1,707,133,000 aggregate principal amount of Notes have been accepted for purchase, excluding the Notes delivered pursuant to the Guaranteed Delivery Procedures. The Company's obligation to complete an Offer with respect to a particular series of Notes validly tendered is conditioned on the satisfaction of conditions described in the Offer to Purchase, including that the aggregate Total Consideration payable for all Notes purchased in the Offers not exceed the Consideration Cap Amount (after giving effect to the increase described above), and on the Consideration Cap Amount (after giving effect to the increase described above) being sufficient to pay the Total Consideration for all validly tendered and not validly withdrawn Notes of such series (after accounting for all validly tendered Notes that have a higher Acceptance Priority Level) (the 'Consideration Cap Condition'). The purchase of all the Notes validly tendered and not validly withdrawn in the Offers (including those anticipated to be tendered pursuant to the Guaranteed Delivery Procedures) would cause the Consideration Cap Condition to not be satisfied with respect to all Offers for the Notes. Accordingly, in accordance with the Consideration Cap Condition, (i) Rogers has accepted for purchase all of the Notes with an Acceptance Priority Level in the table above of 1 through 5 (inclusive), in each case, that have been validly tendered and not validly withdrawn at or prior to the Expiration Date (and will accept all Notes of such series that are properly tendered pursuant to the Guaranteed Delivery Procedures), and (ii) Rogers has not accepted for purchase any of the Notes with an Acceptance Priority Level in the table above of 6 through 8 (inclusive). Upon the terms and subject to the conditions set forth in the Offer to Purchase, Holders whose Notes have been accepted by the Company for purchase in the Offers will receive the applicable Total Consideration specified in the table above for each US$1,000 principal amount of such Notes in cash on the Settlement Date. In addition to the applicable Total Consideration, Holders whose Notes have been accepted by the Company for purchase pursuant to an Offer will receive a cash payment equal to the accrued and unpaid interest on such Notes from and including the immediately preceding interest payment date for such Notes to, but excluding, the Settlement Date (the 'Accrued Coupon Payment'). Interest will cease to accrue on the Settlement Date for all Notes accepted for purchase in the Offers. Under no circumstances will any interest be payable because of any delay in the transmission of funds to Holders by The Depository Trust Company ('DTC') or its participants. The Company has retained BofA Securities, Inc., Citigroup Global Markets Inc., Mizuho Securities USA LLC and Wells Fargo Securities, LLC to act as joint lead dealer managers (the 'Dealer Managers') for the Offers. Questions regarding the terms and conditions for the Offers should be directed to BofA Securities, Inc at +1 (888) 292-0070 (toll-free) or +1 (980) 387-3907 (collect), Citigroup Global Markets Inc. at +1 (800) 558-3745 (toll-free) or +1 (212) 723-6106 (collect), Mizuho Securities USA LLC at +1 (866) 271-7403 (toll-free) or +1 (212) 205-7741 (collect) or Wells Fargo Securities, LLC at +1 (866) 309-6316 (toll-free) or +1 (704) 410-4235 (collect). D.F. King & Co., Inc. is acting as the Information and Tender Agent for the Offers. Questions or requests for assistance related to the Offers or for additional copies of the Offer to Purchase may be directed to D.F. King & Co., Inc. in New York by telephone at +1 (212) 269-5550 (for banks and brokers only) or +1 (877) 478-5047 (for all others toll-free), or by email at rci@ . You may also contact your broker, dealer, commercial bank, trust company or other nominee for assistance concerning the Offers. The Tender Offer Documents can be accessed at the following link: . If the Company terminates any Offer with respect to one or more series of Notes, it will give prompt notice to the Information and Tender Agent, and all Notes tendered pursuant to such terminated Offer will be returned promptly to the tendering Holders thereof. With effect from such termination, any Notes blocked in DTC will be released. Offer and Distribution Restrictions This news release is for informational purposes only. This news release is not an offer to purchase or a solicitation of an offer to sell any Notes or any other securities of the Company or any of its subsidiaries. The Offers are being made solely pursuant to the Offer to Purchase. The Offers are not being made to Holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, 'blue sky' or other laws of such jurisdiction. In any jurisdiction in which the securities or 'blue sky' laws require the Offers to be made by a licensed broker or dealer, the Offers will be deemed to have been made on behalf of the Company by the Dealer Managers or one or more registered brokers or dealers that are licensed under the laws of such jurisdiction. No action has been or will be taken in any jurisdiction that would permit the possession, circulation or distribution of either this news release, the Offer to Purchase or any material relating to the Company or the Notes in any jurisdiction where action for that purpose is required. Accordingly, neither this news release, the Offer to Purchase nor any other offering material or advertisements in connection with the Offers may be distributed or published, in or from any such country or jurisdiction, except in compliance with any applicable rules or regulations of any such country or jurisdiction. Caution Concerning Forward-looking Statements This news release includes 'forward-looking information' within the meaning of applicable Canadian securities laws, and 'forward-looking statements', within the meaning of the United States Private Securities Litigation Reform Act of 1995 (collectively referred to herein as 'forward-looking information' or 'forward-looking statements'), about, among other things, the terms and timing for completion of the Offers, including the acceptance for purchase of Notes validly tendered, the Consideration Cap Amount and the expected Settlement Date. This forward-looking information is based on a number of expectations and assumptions as of the date of this news release. Actual events and results may differ materially from what is expressed or implied by forward‐looking information if the underlying expectations and assumptions prove incorrect or our objectives, strategies or intentions change or as a result of risks, uncertainties and other factors, many of which are beyond our control, including, but not limited to, the risks described under the headings 'About Forward Looking Information' and 'Risks and Uncertainties Affecting our Business' in our management's discussion and analysis for the year ended December 31, 2024. The Company is under no obligation to update or alter any statements containing forward-looking information, whether as a result of new information, future events or otherwise, except as required by law. Forward-looking information is provided herein for the purpose of giving information about the proposed Offers. Readers are cautioned that such information may not be appropriate for other purposes. The Company's obligation to complete an Offer with respect to a particular series of Notes validly tendered is conditioned on the satisfaction of conditions described in the Offer to Purchase, including the Consideration Cap Condition. Accordingly, there can be no assurance that repurchases of the Notes under the Offers will occur at all or at the expected time indicated in this news release. About Rogers Communications Inc. Rogers is Canada's leading communications and entertainment company and its shares are publicly traded on the Toronto Stock Exchange (TSX: RCI.A and RCI.B) and on the New York Stock Exchange (NYSE: RCI). For more information, please visit or . For more information: Investor Relations 1-844-801-4792
